Compare MasTec Inc (MTZ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Sanofi SA — how do they compare? MasTec Inc trades at $282.9 (market cap $21.90B), while Sanofi SA trades at $43.47 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 4.8× MasTec Inc's market cap, and Sanofi SA pays a 5.55% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | SNY | |
|---|---|---|
Market Cap | $21.90B | $104.30B |
Sector | Technology | Health |
52-Week High | $437.51 | $52.34 |
52-Week Low | $172.51 | $41.33 |
Enterprise Value | $24.81B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $283.76, up 5.77% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported record Q2 2026 revenue of $4.374 billion, up 23% year-over-year, and raised its full-year outlook. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show resistance near $283.
The outlook remains positive due to robust infrastructure demand, a record $21.4 billion backlog, and strategic acquisitions like The Superior Group. Risks include execution challenges in communications segments and high valuation multiples. Earnings growth and backlog execution are key catalysts for further upside.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
